Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
SCYNEXIS is developing ibrexafungerp as an oral small-molecule antifungal; this directly aligns with the 'Oral Small Molecule Therapeutics' investable category.
|
$30.05M |
$0.77
-3.75%
|
|
ORLYNVAH is an oral small-molecule therapeutic antibiotic (sulopenem etzadroxil-probenecid).
|
$29.68M |
$0.74
-9.52%
|
|
Lead assets (LTI-3.00, LTI-1.00) target Idiopathic Pulmonary Fibrosis and related rare pulmonary/fibrosis conditions with peptide-based therapeutics, placing Rein Therapeutics in the Biotech - Rare Diseases space.
|
$28.80M |
$1.30
-4.41%
|
|
Biomarker-based diagnostics used to identify patients for targeted therapies align with Companion Diagnostics.
|
$28.79M |
$19.04
-7.65%
|
|
Cadrenal's lead candidate tecarfarin is an oral small molecule anticoagulant, aligning with the Orals Small Molecule Therapeutics tag.
|
$27.59M |
$14.03
+0.14%
|
|
Boundless Bio operates as a biotech oncology company developing cancer therapies targeting ecDNA, fitting the Biotech - Oncology category.
|
$27.53M |
$1.23
-0.81%
|
|
Leap's core assets are antibody-based oncology therapies, placing it squarely in Biotech - Oncology.
|
$26.46M |
$0.64
-4.13%
|
|
Directly provides a proprietary drug-delivery platform (RaniPill GO/HC) for oral biologics.
|
$26.37M |
$0.46
-3.54%
|
|
PBFT02 is Passage Bio's lead gene therapy product, placing the company squarely in the Biotech - Gene Therapy category.
|
$26.32M |
$8.47
-5.57%
|
|
Allocetra is Enlivex's lead product, a macrophage-reprogramming cell therapy, directly fitting the 'Cell Therapy' category.
|
$25.29M |
$1.15
-1.71%
|
|
Ready-to-use pre-filled syringe candidates (Fedsyra and phenylephrine) form part of Talphera's drug delivery strategy.
|
$25.22M |
$1.23
-3.15%
|
|
Biotech cell therapy-oriented tissue regeneration using rhCollagen scaffolds.
|
$25.20M |
$2.20
-6.38%
|
|
PSTV directly develops radiopharmaceutical therapy using Rhenium-186 nanoliposomes (REYOBIQ) for CNS tumors.
|
$24.42M |
$0.72
-7.07%
|
|
Allarity's lead therapy stenoparib targets oncology indications (PARP/WNT inhibitor) representing its core Biotech - Oncology business.
|
$24.28M |
$1.61
-8.52%
|
|
Patented antiviral small-molecule therapeutics (MGX-0024) targeting respiratory illnesses.
|
$24.27M |
$2.20
-4.76%
|
|
The company’s core platforms are cell-based therapies (gamma delta T cells and cord blood-derived NK cells) used to treat cancer and autoimmune diseases.
|
$23.77M |
$2.06
-8.44%
|
|
Company focuses on oncology diagnostics and prognostics, fitting Biotech - Oncology.
|
$23.64M |
$1.47
+2.85%
|
|
Starco acquiring The Starco Group creates a direct Contract Manufacturing capability, aligning with Contract Manufacturing Organizations.
|
$23.53M |
$0.03
+0.83%
|
|
BE-Smart diagnostic test centers on oncology/esophageal cancer detection, aligning with Biotech - Oncology.
|
$21.85M |
$0.53
+1.29%
|
|
Bee venom–based therapeutic for OA/MS pain aligns with Immunology Therapeutics.
|
$21.76M |
$1.88
+0.53%
|
|
Ketamir-2, MIRA-55, and SKNY-1 are all oral small-molecule therapeutics in the company's core pipeline.
|
$21.32M |
$1.26
-6.67%
|
|
Rallybio centers on rare-disease therapies (RLYB116 and RLYB332) and aligns its development strategy around treating rare conditions.
|
$21.26M |
$0.51
-7.11%
|
|
FibroBiologics' core business is fibroblast-based cell therapy with lead candidates CYWC628, CYMS101, and CybroCell, fitting the Biotech - Cell Therapy category.
|
$21.01M |
$0.55
-0.05%
|
|
HT-001 and HT-KIT are oncology-focused assets, placing Hoth Therapeutics squarely in Biotech - Oncology.
|
$20.87M |
$1.58
-5.39%
|
|
Develops internal ophthalmic drug CLS-AX (axitinib injectable suspension) for suprachoroidal delivery, a drug product in development.
|
$20.62M |
$3.98
-8.72%
|
|
Lisata Therapeutics operates in oncology biotech with certepetide as its lead cancer therapy.
|
$20.38M |
$2.37
|
|
Company is a biotech focused on oncology therapeutic development.
|
$20.27M |
$18.43
|
|
EB06 (anti-CXCL10 monoclonal antibody) and EB05/EB07 (paridiprubart-host-directed therapeutics) and EB01 (daniluromer cream) are immunology/inflammatory disease therapeutics developed by Edesa, aligning with Immunology Therapeutics.
|
$20.23M |
$2.76
-4.17%
|
|
Propanc Biopharma's core offering is a cancer therapy (PRP) in preclinical development, aligning with Biotech - Oncology.
|
$20.09M |
$1.73
-6.99%
|
|
NXGEL's revenue is driven by contract manufacturing, including their SilverSeal products and packaging capabilities.
|
$19.67M |
$2.57
-3.02%
|
|
Provides healthcare-related composite parts and healthcare product applications.
|
$19.56M |
$1.15
-3.36%
|
|
Company develops oncology-focused therapies (ENV-105, KROS candidates).
|
$19.55M |
$1.16
-12.12%
|
|
The lead program targeted a rare metabolic disease (PKU), aligning with the Rare Diseases investable theme.
|
$19.51M |
$1.67
-1.30%
|
|
DiversitAb is an antibody Discovery Platform used to generate fully human polyclonal antibodies; directly describes their core platform and product approach.
|
$19.14M |
$2.06
+4.04%
|
|
The company leverages contract manufacturing through 503B outsourcing facilities to produce its proprietary topical sildenafil cream and other products, fitting Contract Manufacturing Organizations as a core capability.
|
$18.76M |
$2.12
-4.93%
|
|
Precise PRP licensing indicates involvement in cell-based regenerative therapies for animals.
|
$18.52M |
$1.28
+1.35%
|
|
Elite manufactures generic pharmaceutical products across CNS and other therapeutic areas (generic drugs).
|
$18.36M |
$0.63
+0.13%
|
|
X4's lead product mavorixafor is an oral small-molecule therapeutic for rare immunodeficiency conditions (WHIM CN).
|
$17.89M |
$3.09
-6.36%
|
|
ABPA and other respiratory conditions targeted by Pulmatrix's assets align with rare-disease/low-incidence biotech therapeutics.
|
$17.42M |
$4.77
+1.27%
|
|
Lead botanical drug Phyto-N targets inflammatory/immune-mediated diseases (ulcerative colitis, atopic dermatitis), aligning with Immunology Therapeutics.
|
$16.76M |
$0.70
-6.82%
|
|
Company's antiviral pipeline centers on small-molecule antivirals (ratutrelvir) targeting SARS-CoV-2.
|
$16.75M |
$3.01
-2.27%
|
|
Core business is private-label contract manufacturing of vitamins, minerals, herbal and other health care products for global customers.
|
$16.44M |
$2.66
-3.28%
|
|
Direct focus on neuropsychiatric CNS therapeutics (roluperidone) for schizophrenia negative symptoms.
|
$16.43M |
$2.35
-2.89%
|
|
PMN is actively developing vaccine programs (PMN311 and PMN400), making Vaccines a direct product category for the company.
|
$16.28M |
$0.50
+4.64%
|
|
PV-10 is Provectus' lead oncology therapeutic developed from Rose Bengal Sodium (RBS).
|
$16.11M |
$0.08
+0.93%
|
|
Emavusertib is an oncology asset, representing Curis's core product focus in cancer therapeutics.
|
$15.90M |
$1.52
-6.17%
|
|
VELDONA low-dose interferon platform targets rare autoimmune/infectious diseases (biotech category Rare Diseases).
|
$15.66M |
$3.77
-4.80%
|
|
NXTC directly develops and pursues Antibody-Drug Conjugates (ADCs) as its lead oncology therapies (LNCB74, SIM0505).
|
$15.54M |
$6.65
+5.59%
|
|
Biotech - Oncology reflects a stated biotech arm (Fuse Biotech) with potential oncology-focused therapies or programs.
|
$15.41M |
$0.24
|
|
Company develops neuropsychiatric therapeutics (BXCL501) for agitation, a CNS/psychiatric drug development program.
|
$15.32M |
$2.53
-3.80%
|
|
PolyPid's PLEX is a proprietary drug delivery platform enabling localized, prolonged release of APIs at the surgical site, core to the business.
|
$15.11M |
$3.15
-3.96%
|
|
Athira's lead program ATH-1105 targets ALS, a CNS neurodegenerative condition, aligning with neuropsychiatric/CNS drug development themes.
|
$14.84M |
$3.80
-3.06%
|
|
TLANDO and pipeline candidates are formulated as oral small‑molecule therapeutics, aligning with the tag.
|
$14.61M |
$2.73
-1.80%
|
|
AYTU's ADHD and pediatric neuropsychiatric portfolio places it in the neuropsychiatric drug development / CNS category.
|
$14.56M |
$2.36
-7.45%
|
|
LB-100 is Lixte's lead oncology drug (PP2A inhibitor) and the core product being developed for cancer indications.
|
$14.28M |
$5.32
-3.80%
|
|
The company explicitly markets an Antibody Discovery Platform as a core capability in its AI-driven antibody development approach.
|
$14.19M |
$0.81
-0.30%
|
|
Lead asset solnerstotug is an oncology monoclonal antibody therapy targeting VISTA.
|
$14.19M |
$11.26
-5.06%
|
|
Company is advancing an oncology-focused biotech platform (FHAB) with lead asset SON-1010, making oncology the core direct business line.
|
$13.96M |
$4.41
-6.96%
|
|
The company licenses RNA interference assets (siRNA) and pursues RNAi therapeutics development as part of its pipeline.
|
$13.56M |
$1.44
-4.64%
|
|
Exclusive KRAS gene-related license, aligning with biotech/gene therapy applications.
|
$13.32M |
$0.12
|
|
LYMPHIR is an FDA-approved targeted immunotherapy for CTCL (cancer), representing a core oncology biotech product.
|
$12.66M |
$1.23
-6.11%
|
|
Longeveron's lead candidate laromestrocel is a mesenchymal stem cell (MSC) based cell therapy.
|
$12.20M |
$0.81
-7.66%
|
|
Directly manufactures autologous stem cell therapy (BRTX-100) for chronic lumbar disc disease, a core cell therapy product line.
|
$12.16M |
$1.62
-5.81%
|
|
Travelan (IMM-124E) and related gut-health antibody products are prophylactic biologics targeting enteric pathogens, aligning with the Vaccines category.
|
$11.80M |
$2.07
-2.36%
|
|
LungFit is described as a drug delivery platform for nitric oxide, i.e., a platform technology for NO delivery.
|
$11.78M |
$2.54
-5.58%
|
|
Biotechnology segment with oncology-focused programs and pipeline support.
|
$11.75M |
$1.29
-4.30%
|
|
Company is actively developing antiviral small-molecule therapeutics across influenza, norovirus/coronavirus, and HCV indications.
|
$11.70M |
$1.15
-7.26%
|
|
IHL-42X and the firm’s other pipeline assets are delivered as oral small-molecule therapeutics (oral drugs).
|
$11.53M |
$0.39
-9.33%
|
|
Core product platform MAR-T cell therapy (multi-antigen T-cell therapy) for cancer.
|
$11.43M |
$1.01
-4.72%
|
|
Company operates in the oncology biotech space, focusing on cancer diagnostics.
|
$11.13M |
$4.08
-7.06%
|
|
Bolt's Boltbody ISAC platform is an antibody discovery/conjugate platform central to its products, qualifying as an 'Antibody Discovery Platform' investment theme.
|
$11.12M |
$5.80
-1.60%
|
|
Directly involved in oncology-focused cellular therapies as a platform for CAR-Macrophages used to treat solid tumors.
|
$10.90M |
$0.24
-6.09%
|
|
OSR Holdings' VAXIMM AG focuses on oral immunotherapies for cancer, aligning with Oncology-focused biotechnology.
|
$10.69M |
$0.55
-9.02%
|
|
PHIO develops innovative oncology therapies leveraging IO and immune modulation in cancer, aligning with Biotech - Oncology.
|
$10.57M |
$2.20
-7.09%
|
|
Gelteq oversees manufacturing of its gel-based delivery systems and relies on CMOs with a dedicated facility, a core contract manufacturing service.
|
$10.55M |
$1.30
-2.99%
|
|
PALI-2108 is an orally administered small-molecule therapeutic, fitting the Oral Small Molecule Therapeutics category.
|
$9.59M |
$2.00
-3.38%
|
|
Direct focus on oncology programs (PDAC) with motixafortide data supporting oncology indications.
|
$9.38M |
$3.91
-5.10%
|
|
Chemrex is transitioning to a biotechnology-focused Contract Development and Manufacturing Organization (CDMO) model.
|
$9.32M |
$5.19
-3.71%
|
|
KALA's lead product KPI-012 is an ophthalmic therapy (cell-free MSC-S secretome) aimed at treating Persistent Corneal Epithelial Defects, aligning with Ophthalmic Drugs.
|
$9.23M |
$1.43
-7.74%
|
|
The company emphasizes proprietary drug formulations and delivery methods as a core moat, mapping to Drug Delivery Platforms.
|
$9.20M |
$0.70
-6.52%
|
|
Aptorum's pipeline includes oncology-focused therapeutics (e.g., SACT-1) in Phase 1, establishing Biotech - Oncology as a core segment.
|
$9.08M |
$1.66
-30.83%
|
|
Directly develops oncology drugs as a biotech company focused on cancer therapeutics.
|
$8.93M |
$0.20
|
|
Directly focused on oncology therapeutics and cancer targets (miR-10b) within a biotech/oncology pipeline.
|
$8.81M |
$10.56
-1.45%
|
|
Ib ezapolstat is an oral small-molecule antibiotic, forming the core product in Acurx's pipeline.
|
$8.78M |
$7.48
+10.49%
|
|
Biomica’s microbiome-based therapeutics for human health (immunology-related therapeutics).
|
$8.76M |
$1.29
-3.01%
|
|
CELZ's ImmCelz and AlloStem platforms are core cell-therapy products/technologies the company develops and advances.
|
$8.61M |
$3.33
-4.31%
|
|
PAVmed's biopharma expansion includes oncology-focused assets, i.e., Biotech - Oncology.
|
$8.61M |
$0.49
-13.83%
|
|
Provides outsourced drug discovery services and CRO-like capabilities (lab work, data analysis).
|
$8.53M |
$14.32
+1.31%
|
|
Active involvement in cell therapy and regenerative medicine through a joint venture in China.
|
$8.46M |
$0.00
-20.00%
|
|
GeoVax directly develops and commercializes vaccines using its MVA vector platform (e.g., GEO-MVAMpox/smallpox and GEO-CM04S1 COVID-19).
|
$8.44M |
$0.56
-7.43%
|
|
Adrulipase targets exocrine pancreatic insufficiency (EPI), a rare disease indication, placing Entero Therapeutics in Biotech - Rare Diseases.
|
$8.32M |
$5.24
+11.25%
|
|
The company develops ophthalmic drugs (KIO-301 and KIO-104) for retinal diseases.
|
$8.22M |
$2.70
-4.26%
|
|
Direct focus on oncology therapies and cancer immunotherapy platforms.
|
$8.21M |
$0.35
|
|
Immunology therapeutics targeting inflammatory conditions (TH023, anti-TNF-α antibody delivery).
|
$7.93M |
$2.98
-7.45%
|
|
Directly focused on oncology biotech development (Biotech - Oncology) with DDR pathway inhibitors.
|
$7.85M |
$1.42
-5.33%
|
|
Medicure’s direct prescription cardiovascular drugs (AGGRASTAT and ZYPITAMAG) place it squarely in the Cardiovascular Drugs category.
|
$7.83M |
$0.75
|
|
Linebacker platform primarily targets oncology indications via electrophilically enhanced polyphenol compounds; aligns with biotech oncology category.
|
$7.69M |
$0.64
+0.47%
|
|
Lead asset is an immunology-focused therapeutic targeting autoimmune diseases (systemic lupus erythematosus and Sjogren's), aligning with Immunology Therapeutics.
|
$7.63M |
$1.40
-11.39%
|
|
Company is pivoting to an individualized therapy for Treatment Resistant Depression, a neuropsychiatric drug development focus.
|
$7.48M |
$2.33
-5.67%
|
|
Addex's strategy and assets focus on neuropsychiatric drug development (e.g., schizophrenia via Neurosterix M4 PAM program, Dipraglurant for brain injury), fitting Neuropsychiatric Drug Development.
|
$7.43M |
$9.44
+7.49%
|
Showing page 7 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
